Posted by Michael Wonder on 19 Aug 2024
Bavarian Nordic submits data to EMA to extend Mpox/smallpox vaccine approval to adolescents
16 August 2024 - Interim results from clinical study show non-inferiority of immune responses from mpox/smallpox vaccination in adolescents and similar safety profile compared to adults, supporting the extension of current approval in Europe later in 2024.
Bavarian Nordic has submitted clinical data to the EMA to support the extension of the Imvanex (MVA-BN) smallpox and mpox vaccine indication to include adolescents 12 to 17 years of age.
